News & Updates

DiaCarta’s ColoScape™ Assay Detects Precancerous Colorectal Cancer Lesions and Colorectal Cancer Mutations with High Sensitivity

11/05/2021

Excerpt from the Press Release: PLEASANTON, Calif., Oct. 27, 2021 /PRNewswire/ — DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the publication of a study in PLOS ONE that demonstrates that DiaCarta’s ColoScape™ Xenonucleic Acid (XNA)-mediated quantitative real-time polymerase chain reactions (qPCR) clamping assay detects mutant cell-free DNA (cfDNA)…

Read More

Biocom California Announces Sixth Annual Life Science Catalyst Award Winners

11/05/2021

Een life science trailblazers under the age of 40 recognized across California Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)–Biocom California, the association representing the California life science industry, today announced the winners of its sixth annual Life Science Catalyst Awards. The awards celebrate the accomplished and up-and-coming…

Read More

XtalPi and Signet Expand AI Drug Discovery Collaboration to Novel Cancer Target

11/04/2021

Excerpt from the Press Release: SHENZHEN, China and BOSTON, Oct. 27, 2021 /PRNewswire/ — Signet Therapeutics and XtalPi Inc., a physics-based, AI-powered drug R&D company, announced the expansion of their AI drug discovery collaboration to include a new first-in-class program against a novel cancer target identified by Signet. The two companies entered into a strategic collaboration in 2020 and…

Read More

Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer

11/04/2021

Excerpt from the Press Release: NEEDHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that data on patient-reported tolerability assessment of intraprostatic injections will be presented in a virtual poster session at the 28th Annual Prostate Cancer Foundation Scientific Retreat.  Date: Thursday, October 28, 2021  Presenter: Laura K. Aguilar, MD, PhD, Chief Medical Officer at…

Read More

UPDATE – Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients

11/04/2021

Abivertinib is an oral capsule (100 mg QD or two 50-mg capsules a day) that potentially reduces cytokine storm associated with acute respiratory distress syndrome (ARDS) in severe hospitalized COVID-19 patients. Preliminary results from two completed Phase 2 studies: US study (N=96) and Brazil study (N=400) have identified an At-Risk COVID-19 Patient Population – Hospitalized COVID patients receiving oxygen support by…

Read More

Biocom California Institute and California Life Sciences Release 2021 Life Sciences Workforce Trends Report for California

11/03/2021

California’s life sciences industry continues to be a consistent engine of economic growth and high-quality job creation for the state Excerpt from the Press Release: SAN DIEGO, LOS ANGELES & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Biocom California Institute, a 501(c)(3) non-profit that supports life science innovation by strengthening the workforce and leaders of tomorrow, and California…

Read More

Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID-19 Vaccine

11/03/2021

Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced a strong nasal IgA antibody response in seropositive and seronegative adults Safety data show that MV-014-012 is highly attenuated, with no serious adverse events reported and no infectious vaccine virus detected from any participants to date MV-014-212 was built on the company’s AttenuBlock™ platform and is…

Read More

Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors

11/03/2021

Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Synthekine Inc., an engineered cytokine therapeutics company, today announced it is advancing its IL-2 partial agonist, STK-012, into clinical investigation following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). Synthekine will evaluate STK-012 in a Phase 1a/1b, open-label, multi-center,…

Read More

Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs

11/02/2021

‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development. ‒Technology is utilized in Entera’s EB613 oral PTH drug for osteoporosis and several other molecules now in development by Entera and in collaboration with pharmaceutical companies. Excerpt from the Press Release: BOSTON and JERUSALEM,…

Read More

Samsung Receives FDA Clearance for AI Algorithms that Detect Lung Nodules in Chest X-rays

11/02/2021

Chest radiograph without Auto Lung Nodule Detection (ALND) and chest radiograph with lung nodule marked. (Photo: Business Wire) Excerpt from the Press Release: DANVERS, Mass.–(BUSINESS WIRE)–NeuroLogica Corp. today announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Auto Lung Nodule Detection (ALND) tool. The offering provides an on-device, computer-assisted detection (CADe)…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives